Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
- Bill and Melinda Gates Foundation
This publication has 40 references indexed in Scilit:
- Merck Ad5/HIV induces broad innate immune activation that predicts CD8 + T-cell responses but is attenuated by preexisting Ad5 immunityProceedings of the National Academy of Sciences, 2012
- SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responsesVaccine, 2012
- Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in ManScience Translational Medicine, 2012
- Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple SpeciesScience Translational Medicine, 2012
- Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeysNature, 2012
- Novel Adenoviruses in Wild Primates: a High Level of Genetic Diversity and Evidence of Zoonotic TransmissionsJournal of Virology, 2011
- New Candidate Vaccines against Blood-StagePlasmodium falciparumMalaria: Prime-Boost Immunization Regimens Incorporating Human and Simian Adenoviral Vectors and Poxviral Vectors Expressing an Optimized Antigen Based on Merozoite Surface Protein 1Infection and Immunity, 2010
- Differential Specificity and Immunogenicity of Adenovirus Type 5 Neutralizing Antibodies Elicited by Natural Infection or ImmunizationJournal of Virology, 2010
- Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in ThailandNew England Journal of Medicine, 2009
- The influence of innate and pre‐existing immunity on adenovirus therapyJournal of Cellular Biochemistry, 2009